Humana (NYSE:HUM) Price Target Raised to $415.00 at Truist Financial

Humana (NYSE:HUM) had its price objective raised by Truist Financial from $320.00 to $415.00 in a research report released on Tuesday, Marketbeat reports. The brokerage currently has a hold rating on the insurance provider’s stock.

Several other research analysts also recently commented on HUM. Royal Bank Of Canada lifted their target price on shares of Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a report on Thursday, July 9th. Morgan Stanley upped their price target on shares of Humana from $217.00 to $249.00 and gave the company an “underweight” rating in a report on Thursday, June 4th. Guggenheim lifted their price objective on Humana from $252.00 to $269.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Oppenheimer raised Humana from an “outperform” rating to an “outperform” rating in a research report on Wednesday, May 20th. Finally, The Goldman Sachs Group increased their target price on Humana from $158.00 to $195.00 and gave the company a “sell” rating in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $325.87.

Humana Stock Up 0.2%

Shares of Humana stock opened at $406.70 on Tuesday. The stock has a market capitalization of $48.83 billion, a P/E ratio of 43.50, a PEG ratio of 2.31 and a beta of 0.71. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $345.52 and a two-hundred day moving average price of $257.26. Humana has a 12-month low of $163.11 and a 12-month high of $415.00.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. During the same quarter last year, the firm posted $11.58 earnings per share. The company’s quarterly revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. Equities analysts expect that Humana will post 9.03 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Tema ETFs LLC increased its holdings in Humana by 7.5% in the 2nd quarter. Tema ETFs LLC now owns 2,071 shares of the insurance provider’s stock valued at $823,000 after buying an additional 145 shares during the period. Harrell Investment Partners LLC acquired a new position in shares of Humana in the 2nd quarter valued at $224,000. Revolve Wealth Partners LLC bought a new position in shares of Humana during the 2nd quarter worth about $442,000. Centurion Wealth Management LLC bought a new position in shares of Humana during the 2nd quarter worth about $321,000. Finally, Valeo Financial Advisors LLC bought a new stake in Humana in the second quarter valued at about $281,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.